Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial.
暂无分享,去创建一个
E. Lemarié | B. Milleron | C. Chastang | D. Moro | E. Quoix | P. Solal-Céligny | A. Depierre | B. Lebeau | N. Badri | J. Clavier | E. Tuchais | J. Cordier | F. Blachon | P. Jacoulet | J. Bréchot | F. Blanchon | D. Herman | M. Besenval | N. Paillot
[1] J. Crowley,et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Fukuoka,et al. A randomized study of cisplatin versus cisplatin plus vindesine for non‐small cell lung carcinoma , 1991, Cancer.
[3] E. Lemarié,et al. A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non‐Small‐Cell Lung Cancer , 1991, American journal of clinical oncology.
[4] M. Rinaldi,et al. Etoposide versus etoposide plus high‐dose cisplatin in the management of advanced non‐small cell lung cancer: Results of a prospective randomized fonicap trial , 1990 .
[5] D. Finkelstein,et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Sculier,et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Hansen,et al. Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Hryniuk Wm. Average relative dose intensity and the impact on design of clinical trials. , 1987, Seminars in oncology.
[9] P. Rocmans,et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. Einhorn,et al. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Gelber,et al. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. , 1985, Cancer treatment reports.
[12] Hongyung Choi,et al. Characteristics of long‐term survivors after treatment for inoperable carcinoma of the lung , 1985, American journal of clinical oncology.
[13] R. Stevenson,et al. Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. , 1984, European journal of cancer & clinical oncology.
[14] N. Martini,et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. , 1981, Annals of internal medicine.
[15] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[16] S. George,et al. Planning the size and duration of a clinical trial studying the time to some critical event. , 1974, Journal of chronic diseases.
[17] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[18] J. Lallemand,et al. 5'-Nor anhydrovinblastine : Prototype of a new class of vinblastine derivatives , 1979 .
[19] D. Cox. Regression Models and Life-Tables , 1972 .